Want to see JP:2160 full AI Analyst Report?
2160 Stock Chart & Stats
¥3370.00
¥50.00(1.64%)
At close: 4:00 PM EST
¥3370.00
¥50.00(1.64%)
Day’s Range― - ―
52-Week Range¥2,112.00 - ¥3,740.00
Previous CloseN/A
Volume492.20K
Average Volume (3M)969.16K
Market Cap
¥159.48B
Enterprise Value¥127.86B
Total Cash (Recent Filing)¥19.87B
Total Debt (Recent Filing)¥5.17B
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Aug 17, 2026EPS Estimate
-2.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-112.69
Shares Outstanding55,843,130
10 Day Avg. Volume1,104,200
30 Day Avg. Volume969,156
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.52
Price to Sales (P/S)4.71
P/FCF Ratio-46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,800.00Price Target Upside12.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)49.7
Revenue Forecast (FY)¥29.67B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained TTM revenue growth of +76.5% indicates expanding product adoption and market traction. Over 2–6 months this supports operating leverage potential: if management converts top-line gains into controlled opex, the company can narrow losses and build a durable profit recovery path.
High Gross MarginsApproximately 74% gross margin indicates strong unit economics and pricing power likely tied to differentiated products or IP. High structural margins provide buffer against SG&A, enabling future operating margin improvement as sales scale and fixed costs are absorbed.
Low Leverage / Strong CapitalizationConservative leverage (debt-to-equity ~0.10) and a large equity base provide financing flexibility and lower refinancing risk. This balance-sheet strength gives time to execute R&D or commercialization plans without immediate liquidity pressure, a durable advantage while margins recover.
Bears Say
Negative Cash GenerationNegative operating and free cash flow means the business currently consumes cash to run operations and invest, forcing reliance on reserves or financing. If negative cash generation persists over several quarters it raises funding, dilution and execution risk, constraining strategic flexibility.
Negative Profitability / Operating LossesA negative TTM net margin and operating losses show the company is not currently converting revenue into profit. Sustained losses erode retained earnings and can impede ROI on R&D and commercialization unless revenue conversion or cost structure materially improves.
Profitability And Balance Sheet VolatilityHistorical swings in leverage and volatile margins reflect execution and capital-allocation risk. Such volatility complicates forecasting and raises the probability that management will need external financing or make trade-offs that dilute long-term returns if underlying profitability does not stabilize.
GNI Group News
2160 FAQ
What was GNI Group Ltd.’s price range in the past 12 months?
GNI Group Ltd. lowest stock price was ¥2112.00 and its highest was ¥3740.00 in the past 12 months.
What is GNI Group Ltd.’s market cap?
GNI Group Ltd.’s market cap is ¥159.48B.
When is GNI Group Ltd.’s upcoming earnings report date?
GNI Group Ltd.’s upcoming earnings report date is Aug 17, 2026 which is in 45 days.
How were GNI Group Ltd.’s earnings last quarter?
GNI Group Ltd. released its earnings results on May 15, 2026. The company reported -¥38.2 earnings per share for the quarter, missing the consensus estimate of -¥2.74 by -¥35.46.
Is GNI Group Ltd. overvalued?
According to Wall Street analysts GNI Group Ltd.’s price is currently Undervalued.
Does GNI Group Ltd. pay dividends?
GNI Group Ltd. does not currently pay dividends.
What is GNI Group Ltd.’s EPS estimate?
GNI Group Ltd.’s EPS estimate is -2.63.
How many shares outstanding does GNI Group Ltd. have?
GNI Group Ltd. has 55,843,130 shares outstanding.
What happened to GNI Group Ltd.’s price movement after its last earnings report?
GNI Group Ltd. reported an EPS of -¥38.2 in its last earnings report, missing expectations of -¥2.74. Following the earnings report the stock price went down -1.99%.
Which hedge fund is a major shareholder of GNI Group Ltd.?
Currently, no hedge funds are holding shares in JP:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GNI Group Ltd.
GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently available for the treatment of idiopathic pulmonary fibrosis. Beyond this, Etuary is undergoing further clinical evaluation: it is in Phase III trials for connective tissue disease-associated interstitial lung disease, and in Phase II along with a pre-Phase III pilot study for radiation pneumonitis. Investigations are also underway for its application in diabetic nephropathy. GNI Group Ltd.'s pipeline additionally features F351, which is in Phase II development for liver fibrosis; F573, an early-stage compound in pre-clinical testing for acute-on-chronic liver failure; and Tamibarotene, intended for the treatment of acute promyelocytic leukemia. Established in 2001, the company's headquarters are located in Tokyo, Japan.
2160 Stock 12 Month Forecast
Average Price Target
¥3,800.00
▲(12.76% Upside)
Technical Analysis
Options Prices
Currently, No data available
---